Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Holdings Lifted by Huntington National Bank

Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 91.8% in the third quarter, Holdings Channel reports. The firm owned 94 shares of the biopharmaceutical company’s stock after buying an additional 45 shares during the period. Huntington National Bank’s holdings in Alnylam Pharmaceuticals were worth $26,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Janney Montgomery Scott LLC lifted its stake in shares of Alnylam Pharmaceuticals by 47.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 2,775 shares of the biopharmaceutical company’s stock valued at $415,000 after purchasing an additional 892 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Alnylam Pharmaceuticals by 30.3% in the first quarter. Acadian Asset Management LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 386 shares in the last quarter. Ontario Teachers Pension Plan Board acquired a new position in Alnylam Pharmaceuticals during the first quarter worth $274,000. Finally, Covestor Ltd lifted its position in shares of Alnylam Pharmaceuticals by 105.0% in the first quarter. Covestor Ltd now owns 732 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 375 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 0.9 %

Shares of Alnylam Pharmaceuticals stock opened at $234.27 on Wednesday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The firm has a market capitalization of $30.22 billion, a PE ratio of -89.42 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company’s fifty day moving average price is $274.10 and its two-hundred day moving average price is $236.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.15 earnings per share. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ALNY shares. The Goldman Sachs Group raised Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the company from $198.00 to $370.00 in a report on Friday, August 16th. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 11th. Finally, Raymond James upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.